approval
saveKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
community read0 votes
Sponsor: GENENTECH. Form: VIAL. Route: SINGLE-USE
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalMar 26, 2026 · 190d ago
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalMay 14, 2025 · 506d ago
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalSep 27, 2020 · 2196d ago
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalMay 3, 2019 · 2709d ago
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalDec 18, 2018 · 2845d ago
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalSep 20, 2018 · 2934d ago
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalJul 25, 2016 · 3721d ago
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalApr 28, 2016 · 3809d ago
same company · ±60 days · 5
- approvalfaricimab: VABYSMO (FARICIMAB-SVOA) — FDA approvalJan 28, 2022
- approvalobinutuzumab: GAZYVA (OBINUTUZUMAB) — FDA approvalFeb 14, 2022
- approvalatezolizumab: TECENTRIQ (ATEZOLIZUMAB) — FDA approvalJan 21, 2022
- approvaltocilizumab: ACTEMRA (TOCILIZUMAB) — FDA approvalFeb 28, 2022
- approvaltocilizumab: ACTEMRA (TOCILIZUMAB) — FDA approvalFeb 28, 2022
comments(0)
5-min edit window · permanent after that